Renaissance Technologies’s Lucid Diagnostics LUCD Stock Holding History

Renaissance Technologies’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$76.3K	Sell	71,300 -428,361	-86%	-$462K	﹤0.01%	3010
2026 Q1	$575K	Sell	499,661 -326,866	-40%	-$416K	﹤0.01%	2545
2025 Q4	$901K	Buy	826,527 +532,894	+181%	+$596K	﹤0.01%	2338
2025 Q3	$297K	Buy	293,633 +50,354	+21%	+$55K	﹤0.01%	3003
2025 Q2	$280K	Sell	243,279 -215,786	-47%	-$279K	﹤0.01%	3065
2025 Q1	$684K	Buy	+459,065	New	+$551K	﹤0.01%	2611
2022 Q1	–	Sell	-20,000	Closed	-$107K	–	4315
2021 Q4	$107K	Buy	+20,000	New	+$162K	﹤0.01%	3668

Other funds holding LUCD

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Renaissance Technologies's LUCD Position: Q2 2026 in Review

Renaissance Technologies reduced its Lucid Diagnostics (LUCD) stake by 86% in Q2 2026, selling an estimated $462K and leaving 71,300 shares worth $76.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3010.

Renaissance Technologies first reported a position in LUCD in Q4 2021 and has held it in 7 quarters since. The position peaked at $901K in Q4 2025. 115 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

Renaissance Technologies held 71,300 shares of Lucid Diagnostics worth $76.3K as of Q2 2026.
Renaissance Technologies sold 428,361 Lucid Diagnostics shares in Q2 2026, an estimated $462K.
Lucid Diagnostics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #3010 holding.
Renaissance Technologies first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 7 quarters since.
Renaissance Technologies's Lucid Diagnostics position peaked at $901K in Q4 2025.
115 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.